DCM
AXSM icon

Driehaus Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Driehaus Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.4M Buy
292,370
+71,852
+33% +$12.4M 0.36% 98
2025
Q4 		$40.3M Sell
220,518
-2,890
-1% -$403K 0.27% 123
2025
Q3 		$27.1M Buy
223,408
+128
+0.1% +$14.4K 0.19% 168
2025
Q2 		$23.3M Buy
223,280
+9,141
+4% +$968K 0.19% 161
2025
Q1 		$25M Buy
+214,139
New +$24.4M 0.24% 128
2024
Q2 		– Sell
-204,699
Closed -$16.3M – 371
2024
Q1 		$16.3M Sell
204,699
-61,143
-23% -$5.13M 0.16% 184
2023
Q4 		$21.2M Buy
265,842
+16,953
+7% +$1.13M 0.25% 127
2023
Q3 		$17.4M Buy
248,889
+117
+0% +$8.75K 0.23% 149
2023
Q2 		$17.9M Buy
248,772
+82,267
+49% +$6.07M 0.23% 143
2023
Q1 		$10.3M Sell
166,505
-66,590
-29% -$4.37M 0.14% 216
2022
Q4 		$18M Buy
+233,095
New +$13.9M 0.27% 127
2020
Q3 		– Sell
-241,284
Closed -$19.9M – 393
2020
Q2 		$19.9M Sell
241,284
-21,257
-8% -$1.64M 0.48% 60
2020
Q1 		$15.4M Sell
262,541
-13,176
-5% -$1.07M 0.52% 56
2019
Q4 		$28.5M Buy
+275,717
New +$11.1M 0.76% 26

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Driehaus Capital Management's AXSM Position: Q1 2026 in Review

Driehaus Capital Management increased its Axsome Therapeutics (AXSM) stake by 33% in Q1 2026, buying an estimated $12.4M and bringing the position to 292,370 shares worth $49.4M. The position accounts for 0.36% of the portfolio, ranked #98.

Driehaus Capital Management first reported a position in AXSM in Q4 2019 and has held it in 14 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Driehaus Capital Management held 292,370 shares of Axsome Therapeutics worth $49.4M as of Q1 2026.
  • Driehaus Capital Management bought 71,852 Axsome Therapeutics shares in Q1 2026, an estimated $12.4M.
  • Axsome Therapeutics made up 0.36% of Driehaus Capital Management's portfolio in Q1 2026, its #98 holding.
  • Driehaus Capital Management first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 14 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.